News & Updates
Filter by Specialty:
177Lu-PSMA-617 improves rPFS vs ARPI switch in taxane-naïve mCRPC patients
14 Nov 2023
byChristina Lau
The prostate-specific membrane antigen (PSMA)–targeted radioligand, lutetium-177 (177Lu)–PSMA-617, improves radiographic progression-free survival (rPFS) vs androgen receptor pathway inhibitor (ARPI) switch and has a favourable safety profile in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on one prior second-generation ARPI, results of the phase III PSMAfore trial have shown.
177Lu-PSMA-617 improves rPFS vs ARPI switch in taxane-naïve mCRPC patients
14 Nov 2023Multimodal intervention reduces second-line antibiotic prescriptions for UTI
13 Nov 2023
byStephen Padilla
A multimodal intervention applied in general practice results in a significant decrease in antibiotic prescribing and an increase in guideline adherence among women with uncomplicated urinary tract infection (UTI), a study has shown.